Evaluation of the relationship between anxiety during withdrawal and stress-induced reinstatement of cocaine seeking.
The initial termination of cocaine consumption in human addicts is associated with heightened anxiety states and low levels of craving. Craving, however, tends to increase progressively over time, remains high for extended periods of time, and can be exacerbated by stressors, leading to relapse. Laboratory rats, likewise, exhibit heightened states of anxiety after withdrawal from drug, and follow a time course of cocaine seeking that parallels the time course of craving reported in humans. In addition, laboratory rats show heightened susceptibility to relapse when exposed to stressors after extended periods of withdrawal, and exhibit persistent and heightened expressions of stress-induced anxiety. The general objective of this paper is to consider the relationship between anxiety states after withdrawal from cocaine and stress-induced reinstatement of cocaine seeking in laboratory rats, and to identify the neural substrates involved. The focus of the review is on studies addressing the roles of corticotropin-releasing factor (CRF) and noradrenaline pathways of the extended amygdala circuitry, and their direct or indirect interactions with the mesocorticolimbic dopamine system, in anxiety after withdrawal from cocaine and stress-induced reinstatement of cocaine seeking. Furthermore, the effects of time after withdrawal from cocaine and amount of cocaine exposure during self-administration on the activity of CRF, noradrenaline, and dopamine pathways of the extended amygdala and mesocorticolimbic systems will be considered. The review will highlight how changing levels of activity within these systems may serve to alter the nature of the relationship between anxiety and stress-induced reinstatement of cocaine seeking at different times after withdrawal from cocaine.
Erb
Suzanne
S
Center for Neurobiology of Stress, Department of Psychology, University of Toronto Scarborough, Toronto, Ontario, Canada M1C 1A4. erb@utsc.utoronto.ca
D000818:Animals; D001007:Anxiety; D001921:Brain / Q000378:metabolism; D003042:Cocaine / Q000008:administration & dosage*; D019970:Cocaine-Related Disorders / Q000503:physiopathology* / Q000523:psychology*; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D012008:Recurrence; D012646:Self Administration; D013315:Stress, Psychological; D013375:Substance Withdrawal Syndrome / Q000523:psychology*
D003346:Corticotropin-Releasing Hormone; D003042:Cocaine; D004298:Dopamine; D009638:Norepinephrine